[{"id":"96d265fb-788a-46ce-b813-8e0bb6f372ba","acronym":"","url":"https://clinicaltrials.gov/study/NCT06692179","created_at":"2025-02-25T13:57:07.037Z","updated_at":"2025-02-25T13:57:07.037Z","phase":"Phase 1","brief_title":"An Open-Label, Pilot Clinical Trial To Test The Safety And Feasibility Of A Suspension of Freeze-dried Microbiota In Patients Undergoing Colon Resection","source_id_and_acronym":"NCT06692179","lead_sponsor":"University of Minnesota","biomarkers":" CD14 • TJP1","pipe":"","alterations":" ","tags":["CD14 • TJP1"],"overall_status":"Recruiting","enrollment":" Enrollment 40","initiation":"Initiation: 02/18/2025","start_date":" 02/18/2025","primary_txt":" Primary completion: 02/18/2027","primary_completion_date":" 02/18/2027","study_txt":" Completion: 02/18/2027","study_completion_date":" 02/18/2027","last_update_posted":"2025-02-20"},{"id":"56bb338a-9a55-47ed-87d8-9a54d97136da","acronym":"","url":"https://clinicaltrials.gov/study/NCT03595124","created_at":"2021-01-18T17:40:40.562Z","updated_at":"2025-02-25T16:31:25.872Z","phase":"Phase 2","brief_title":"A Study to Compare Treatments for a Type of Kidney Cancer Called TFE/Translocation Renal Cell Carcinoma (tRCC)","source_id_and_acronym":"NCT03595124","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" CD8 • PD-1 • CD38 • PTPRC • CD69 • TFE3 • CD14 • CD24 • ITGAM • FOXP3","pipe":" | ","alterations":" PD-L1 expression","tags":["CD8 • PD-1 • CD38 • PTPRC • CD69 • TFE3 • CD14 • CD24 • ITGAM • FOXP3"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Opdivo (nivolumab) • axitinib • ABP 206 (nivolumab biosimilar) • CMAB 819 (nivolumab biosimilar)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 15","initiation":"Initiation: 01/08/2019","start_date":" 01/08/2019","primary_txt":" Primary completion: 09/30/2024","primary_completion_date":" 09/30/2024","study_txt":" Completion: 01/23/2026","study_completion_date":" 01/23/2026","last_update_posted":"2025-02-07"},{"id":"73e8506b-a82d-41df-b4ff-414021e9babc","acronym":"","url":"https://clinicaltrials.gov/study/NCT03042221","created_at":"2021-01-18T14:58:44.313Z","updated_at":"2025-02-25T16:36:51.399Z","phase":"","brief_title":"Early Rebiopsy to Identify Biomarkers of Tumor Cell Survival Following EGFR, ALK, ROS1 or BRAF TKI Therapy","source_id_and_acronym":"NCT03042221","lead_sponsor":"University of Colorado, Denver","biomarkers":" BRAF • ALK • ROS1 • CD8 • CDH1 • CD14 • VIM • MRC1","pipe":" | ","alterations":" BRAF V600E • EGFR mutation • BRAF V600 • EGFR L858R • ROS1 fusion","tags":["BRAF • ALK • ROS1 • CD8 • CDH1 • CD14 • VIM • MRC1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRAF V600E • EGFR mutation • BRAF V600 • EGFR L858R • ROS1 fusion"],"overall_status":"Recruiting","enrollment":" Enrollment 100","initiation":"Initiation: 05/10/2016","start_date":" 05/10/2016","primary_txt":" Primary completion: 11/01/2026","primary_completion_date":" 11/01/2026","study_txt":" Completion: 09/30/2027","study_completion_date":" 09/30/2027","last_update_posted":"2025-02-06"},{"id":"9b80d640-ac33-4411-ad4d-9614359a1e32","acronym":"","url":"https://clinicaltrials.gov/study/NCT02265536","created_at":"2025-07-19T14:00:09.317Z","updated_at":"2025-07-19T14:00:09.317Z","phase":"Phase 1","brief_title":"A Study of LY3022855 In Participants With Breast or Prostate Cancer","source_id_and_acronym":"NCT02265536","lead_sponsor":"Eli Lilly and Company","biomarkers":" CD8 • PD-1 • IFNG • IL6 • LAG3 • TNFA • CTLA4 • IL2 • ICOS • IL10 • CD14 • FOXP3 • IL1B","pipe":"","alterations":" ","tags":["CD8 • PD-1 • IFNG • IL6 • LAG3 • TNFA • CTLA4 • IL2 • ICOS • IL10 • CD14 • FOXP3 • IL1B"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e LY3022855"],"overall_status":"Completed","enrollment":" Enrollment 34","initiation":"Initiation: 05/01/2015","start_date":" 05/01/2015","primary_txt":" Primary completion: 11/03/2017","primary_completion_date":" 11/03/2017","study_txt":" Completion: 11/03/2017","study_completion_date":" 11/03/2017","last_update_posted":"2024-10-28"},{"id":"114d9c89-e0e5-473e-a324-f2022f9b4244","acronym":"","url":"https://clinicaltrials.gov/study/NCT04465643","created_at":"2021-01-18T21:27:49.677Z","updated_at":"2025-02-25T14:29:26.270Z","phase":"Phase 1","brief_title":"Neoadjuvant Nivolumab Plus Ipilimumab for Newly Diagnosed Malignant Peripheral Nerve Sheath Tumor","source_id_and_acronym":"NCT04465643","lead_sponsor":"Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins","biomarkers":" PD-L1 • CD20 • CD8 • PD-1 • LAG3 • CD276 • CTLA4 • PD-L2 • VTCN1 • HAVCR2 • IL2RA • CD163 • TIGIT • PTPRC • NCAM1 • ICOS • CD14 • CD68 • GZMB • ITGAM • BTLA • FOXP3 • MRC1 • ISG20","pipe":"","alterations":" ","tags":["PD-L1 • CD20 • CD8 • PD-1 • LAG3 • CD276 • CTLA4 • PD-L2 • VTCN1 • HAVCR2 • IL2RA • CD163 • TIGIT • PTPRC • NCAM1 • ICOS • CD14 • CD68 • GZMB • ITGAM • BTLA • FOXP3 • MRC1 • ISG20"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Opdivo (nivolumab) • Yervoy (ipilimumab)"],"overall_status":"Recruiting","enrollment":" Enrollment 18","initiation":"Initiation: 06/08/2021","start_date":" 06/08/2021","primary_txt":" Primary completion: 06/01/2025","primary_completion_date":" 06/01/2025","study_txt":" Completion: 08/01/2026","study_completion_date":" 08/01/2026","last_update_posted":"2024-06-21"},{"id":"3211efeb-73ba-4748-919e-faedd3fb0a0b","acronym":"","url":"https://clinicaltrials.gov/study/NCT05091866","created_at":"2024-06-15T04:11:56.215Z","updated_at":"2024-07-02T16:34:27.107Z","phase":"Phase 1","brief_title":"Natural Progesterone for the Treatment of Recurrent Glioblastoma","source_id_and_acronym":"NCT05091866","lead_sponsor":"Emory University","biomarkers":" PGR • CD14 • CHI3L1 • MMP9 • CRP • FCER2","pipe":"","alterations":" ","tags":["PGR • CD14 • CHI3L1 • MMP9 • CRP • FCER2"],"overall_status":"Recruiting","enrollment":" Enrollment 32","initiation":"Initiation: 04/11/2022","start_date":" 04/11/2022","primary_txt":" Primary completion: 08/25/2025","primary_completion_date":" 08/25/2025","study_txt":" Completion: 08/25/2026","study_completion_date":" 08/25/2026","last_update_posted":"2024-06-11"},{"id":"8a617f1a-04a1-44fa-9406-0c4b9b9170e3","acronym":"BEAUTY","url":"https://clinicaltrials.gov/study/NCT03979508","created_at":"2021-01-18T19:34:12.469Z","updated_at":"2024-07-02T16:35:07.182Z","phase":"Phase 2","brief_title":"Abemaciclib in Treating Patients With Surgically Resectable, Chemotherapy Resistant, Triple Negative Breast Cancer","source_id_and_acronym":"NCT03979508 - BEAUTY","lead_sponsor":"Mayo Clinic","biomarkers":" HER-2 • ER • PGR • CD20 • JAK2 • CD8 • CDH1 • CCR4 • IL2RA • PTPRC • NCAM1 • CCR5 • CCR7 • CD14 • CD27 • GZMB • HLA-B • NLRC5 • FOXP3 • IKZF2 • IL3RA • STAT1 • CXCR3 • CXCR5 • ITGAX • PRF1 • SNAI2 • TAP1 • CCR6 • CEACAM8 • DDX58 • HLA-C • IFNL1 • IFNL2 • IFNL3 • ITGB1 • KLRB1","pipe":" | ","alterations":" JAK2 amplification","tags":["HER-2 • ER • PGR • CD20 • JAK2 • CD8 • CDH1 • CCR4 • IL2RA • PTPRC • NCAM1 • CCR5 • CCR7 • CD14 • CD27 • GZMB • HLA-B • NLRC5 • FOXP3 • IKZF2 • IL3RA • STAT1 • CXCR3 • CXCR5 • ITGAX • PRF1 • SNAI2 • TAP1 • CCR6 • CEACAM8 • DDX58 • HLA-C • IFNL1 • IFNL2 • IFNL3 • ITGB1 • KLRB1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e JAK2 amplification"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Verzenio (abemaciclib)"],"overall_status":"Recruiting","enrollment":" Enrollment 200","initiation":"Initiation: 01/10/2020","start_date":" 01/10/2020","primary_txt":" Primary completion: 07/31/2024","primary_completion_date":" 07/31/2024","study_txt":" Completion: 07/31/2024","study_completion_date":" 07/31/2024","last_update_posted":"2024-04-29"},{"id":"db270b5b-2574-4ac2-885f-2a24d956e453","acronym":"","url":"https://clinicaltrials.gov/study/NCT06341478","created_at":"2024-04-02T23:41:45.637Z","updated_at":"2024-07-02T16:35:11.918Z","phase":"","brief_title":"Investigator Grant (IG) 2022 27746","source_id_and_acronym":"NCT06341478","lead_sponsor":"IRCCS San Raffaele","biomarkers":" CD14","pipe":"","alterations":" ","tags":["CD14"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • Opdivo (nivolumab) • albumin-bound paclitaxel"],"overall_status":"Recruiting","enrollment":" Enrollment 153","initiation":"Initiation: 03/15/2024","start_date":" 03/15/2024","primary_txt":" Primary completion: 03/15/2026","primary_completion_date":" 03/15/2026","study_txt":" Completion: 03/15/2027","study_completion_date":" 03/15/2027","last_update_posted":"2024-04-02"},{"id":"99a93edf-b954-4a4c-b660-2bb38fc9221e","acronym":"","url":"https://clinicaltrials.gov/study/NCT05809128","created_at":"2023-04-12T14:03:12.772Z","updated_at":"2024-07-02T16:35:13.058Z","phase":"","brief_title":"Multidisciplinary Approach to Breast Cancer Through the Study of Altered Transcriptomic and Immune Accompanied by the Identification of Extractable Markers From the Radiodiagnostic Bioimaging","source_id_and_acronym":"NCT05809128","lead_sponsor":"IRCCS SYNLAB SDN","biomarkers":" CD8 • PTPRC • NCAM1 • CD14","pipe":"","alterations":" ","tags":["CD8 • PTPRC • NCAM1 • CD14"],"overall_status":"Recruiting","enrollment":" Enrollment 1000","initiation":"Initiation: 05/29/2019","start_date":" 05/29/2019","primary_txt":" Primary completion: 01/31/2023","primary_completion_date":" 01/31/2023","study_txt":" Completion: 06/30/2025","study_completion_date":" 06/30/2025","last_update_posted":"2024-03-25"},{"id":"cb11cd54-0bac-4f20-bf14-95c5e18524bf","acronym":"","url":"https://clinicaltrials.gov/study/NCT04187703","created_at":"2022-04-24T09:01:41.679Z","updated_at":"2024-07-02T16:35:15.464Z","phase":"Phase 1","brief_title":"5-Azacitidine and Decitabine Epigenetic Therapy for Myeloid Malignancies","source_id_and_acronym":"NCT04187703","lead_sponsor":"Benjamin Tomlinson","biomarkers":" ABL1 • BCR • CD14 • DCK • DNMT1 • ITGAM • NT5C","pipe":" | ","alterations":" Chr del(5q)","tags":["ABL1 • BCR • CD14 • DCK • DNMT1 • ITGAM • NT5C"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Chr del(5q)"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e azacitidine • decitabine"],"overall_status":"Recruiting","enrollment":" Enrollment 20","initiation":"Initiation: 11/16/2020","start_date":" 11/16/2020","primary_txt":" Primary completion: 12/01/2024","primary_completion_date":" 12/01/2024","study_txt":" Completion: 12/01/2025","study_completion_date":" 12/01/2025","last_update_posted":"2024-03-11"},{"id":"3e645071-4216-4aec-a0bd-0e6e40f1d02a","acronym":"S1607","url":"https://clinicaltrials.gov/study/NCT02965716","created_at":"2021-01-18T14:34:36.597Z","updated_at":"2024-07-02T16:35:26.748Z","phase":"Phase 2","brief_title":"Talimogene Laherparepvec and Pembrolizumab in Treating Patients With Stage III-IV Melanoma","source_id_and_acronym":"NCT02965716 - S1607","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" TMB • CD8 • PD-1 • CD14 • FOXP3 • CD80 • CD86","pipe":" | ","alterations":" CD8 expression","tags":["TMB • CD8 • PD-1 • CD14 • FOXP3 • CD80 • CD86"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD8 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • Imlygic (talimogene laherparepvec)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 42","initiation":"Initiation: 06/05/2018","start_date":" 06/05/2018","primary_txt":" Primary completion: 06/30/2023","primary_completion_date":" 06/30/2023","study_txt":" Completion: 11/05/2024","study_completion_date":" 11/05/2024","last_update_posted":"2023-12-08"},{"id":"09b806b7-5ada-4ec4-bf5b-2c8ce1a24629","acronym":"BACCARAT","url":"https://clinicaltrials.gov/study/NCT02605512","created_at":"2022-06-04T15:45:36.960Z","updated_at":"2024-07-02T16:35:29.944Z","phase":"","brief_title":"BreAst Cancer and Cardiotoxicity Induced by RAdioTherapy: the BACCARAT Study","source_id_and_acronym":"NCT02605512 - BACCARAT","lead_sponsor":"Sophie JACOB","biomarkers":" IL6 • CD14 • MIR34A • IL18 • CD31 • MIR17 • MIR182 • MIR18A • PECAM1 • CRP • ITGA2B • MIR140 • MIR145 • MIR150 • MIR22 • MIR423","pipe":"","alterations":" ","tags":["IL6 • CD14 • MIR34A • IL18 • CD31 • MIR17 • MIR182 • MIR18A • PECAM1 • CRP • ITGA2B • MIR140 • MIR145 • MIR150 • MIR22 • MIR423"],"overall_status":"Completed","enrollment":" Enrollment 118","initiation":"Initiation: 10/01/2015","start_date":" 10/01/2015","primary_txt":" Primary completion: 02/01/2020","primary_completion_date":" 02/01/2020","study_txt":" Completion: 02/01/2020","study_completion_date":" 02/01/2020","last_update_posted":"2023-11-08"},{"id":"98b71e20-18b4-4643-a7a1-0a9a241a26a3","acronym":"","url":"https://clinicaltrials.gov/study/NCT05406531","created_at":"2022-06-06T12:57:29.839Z","updated_at":"2024-07-02T16:35:32.617Z","phase":"","brief_title":"The Effectiveness of Psychological Interventions in Psycho-neuroendocrine-immune Network in Breast Cancer Survivors","source_id_and_acronym":"NCT05406531","lead_sponsor":"Masaryk University","biomarkers":" CD8 • IL6 • IL2 • NCAM1 • IL10 • CD14 • IL17A • CRP","pipe":"","alterations":" ","tags":["CD8 • IL6 • IL2 • NCAM1 • IL10 • CD14 • IL17A • CRP"],"overall_status":"Recruiting","enrollment":" Enrollment 440","initiation":"Initiation: 06/06/2022","start_date":" 06/06/2022","primary_txt":" Primary completion: 01/01/2025","primary_completion_date":" 01/01/2025","study_txt":" Completion: 06/01/2025","study_completion_date":" 06/01/2025","last_update_posted":"2023-10-19"},{"id":"fae39971-a2c0-4146-ae98-d52ecfefd832","acronym":"CHEMOFAST","url":"https://clinicaltrials.gov/study/NCT04247464","created_at":"2021-01-18T20:38:41.351Z","updated_at":"2024-07-02T16:35:34.625Z","phase":"","brief_title":"Short-term Fasting as an Enhancer of Chemotherapy: Pilot Clinical Study on Colorectal Carcinoma Patients","source_id_and_acronym":"NCT04247464 - CHEMOFAST","lead_sponsor":"IMDEA Food","biomarkers":" CD8 • CEACAM5 • IL2RA • IL7R • NCAM1 • CD14 • PDK4 • CDKN1A • ISG20","pipe":"","alterations":" ","tags":["CD8 • CEACAM5 • IL2RA • IL7R • NCAM1 • CD14 • PDK4 • CDKN1A • ISG20"],"overall_status":"Completed","enrollment":" Enrollment 11","initiation":"Initiation: 09/23/2020","start_date":" 09/23/2020","primary_txt":" Primary completion: 02/01/2023","primary_completion_date":" 02/01/2023","study_txt":" Completion: 02/01/2023","study_completion_date":" 02/01/2023","last_update_posted":"2023-10-05"},{"id":"8bfb48a5-7a5e-4365-8828-e51c1648bb77","acronym":"ATPIC","url":"https://clinicaltrials.gov/study/NCT05867004","created_at":"2023-05-19T13:04:57.952Z","updated_at":"2024-07-02T16:35:47.091Z","phase":"","brief_title":"Blocking TNF to Potentiate the ICI-dependent Immune Awakening in Melanoma","source_id_and_acronym":"NCT05867004 - ATPIC","lead_sponsor":"Institut Claudius Regaud","biomarkers":" CD8 • IFNG • CD4 • CD14 • CD68 • FOXP3 • IL17A","pipe":" | ","alterations":" HLA-A2 positive","tags":["CD8 • IFNG • CD4 • CD14 • CD68 • FOXP3 • IL17A"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HLA-A2 positive"],"overall_status":"Recruiting","enrollment":" Enrollment 100","initiation":"Initiation: 01/01/2023","start_date":" 01/01/2023","primary_txt":" Primary completion: 11/30/2023","primary_completion_date":" 11/30/2023","study_txt":" Completion: 12/31/2026","study_completion_date":" 12/31/2026","last_update_posted":"2023-05-26"},{"id":"7d2a47ff-9cf7-49c0-a990-f38b132df74e","acronym":"Agility","url":"https://clinicaltrials.gov/study/NCT05615883","created_at":"2022-11-14T14:58:23.397Z","updated_at":"2024-07-02T16:36:00.503Z","phase":"","brief_title":"Effects of Acute and Chronic Exercise on Myeloid-Derived Suppressor Cells in Melanoma Patients","source_id_and_acronym":"NCT05615883 - Agility","lead_sponsor":"Fondazione IRCCS Istituto Nazionale dei Tumori, Milano","biomarkers":" IL6 • TNFA • CXCL8 • IL10 • CD14 • CCL2 • IL1B","pipe":"","alterations":" ","tags":["IL6 • TNFA • CXCL8 • IL10 • CD14 • CCL2 • IL1B"],"overall_status":"Recruiting","enrollment":" Enrollment 20","initiation":"Initiation: 01/20/2020","start_date":" 01/20/2020","primary_txt":" Primary completion: 02/28/2023","primary_completion_date":" 02/28/2023","study_txt":" Completion: 03/31/2023","study_completion_date":" 03/31/2023","last_update_posted":"2022-11-14"},{"id":"d3399d53-3142-4fb8-8731-3da5f0cf0026","acronym":"TITAN-RCC","url":"https://clinicaltrials.gov/study/NCT02917772","created_at":"2021-08-04T19:53:08.805Z","updated_at":"2025-02-25T14:36:42.250Z","phase":"Phase 2","brief_title":"Tailored ImmunoTherapy Approach With Nivolumab in Subjects With Metastatic or Advanced Renal Cell Carcinoma","source_id_and_acronym":"NCT02917772 - TITAN-RCC","lead_sponsor":"AIO-Studien-gGmbH","biomarkers":" CD8 • PD-1 • PD-L2 • IL2RA • CD69 • ICOS • IL10 • CD14 • CD27 • LAMP1 • ITGAM • FAS • FOXP3 • IL17A • IL3RA • ITGAX • B3GAT1 • CD1C • CLEC4C","pipe":" | ","alterations":" PD-L1 expression","tags":["CD8 • PD-1 • PD-L2 • IL2RA • CD69 • ICOS • IL10 • CD14 • CD27 • LAMP1 • ITGAM • FAS • FOXP3 • IL17A • IL3RA • ITGAX • B3GAT1 • CD1C • CLEC4C"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Opdivo (nivolumab) • Yervoy (ipilimumab)"],"overall_status":"Completed","enrollment":" Enrollment 200","initiation":"Initiation: 10/01/2016","start_date":" 10/01/2016","primary_txt":" Primary completion: 10/01/2021","primary_completion_date":" 10/01/2021","study_txt":" Completion: 10/01/2022","study_completion_date":" 10/01/2022","last_update_posted":"2022-10-06"},{"id":"290b7fc0-2551-4b8e-8a40-119d81d3738c","acronym":"VitDURO","url":"https://clinicaltrials.gov/study/NCT04197089","created_at":"2021-01-18T20:27:15.791Z","updated_at":"2024-07-02T16:36:06.166Z","phase":"Phase 4","brief_title":"Biological Effect of Vitamin D in Patients With Urothelial Carcinoma","source_id_and_acronym":"NCT04197089 - VitDURO","lead_sponsor":"Germans Trias i Pujol Hospital","biomarkers":" FGFR3 • CDH1 • CD14 • CDH2 • KRT14 • CDKN1A • G0S2 • GAPDH • KRT20 • KRT5","pipe":"","alterations":" ","tags":["FGFR3 • CDH1 • CD14 • CDH2 • KRT14 • CDKN1A • G0S2 • GAPDH • KRT20 • KRT5"],"overall_status":"Completed","enrollment":" Enrollment 2","initiation":"Initiation: 02/11/2020","start_date":" 02/11/2020","primary_txt":" Primary completion: 11/22/2021","primary_completion_date":" 11/22/2021","study_txt":" Completion: 11/22/2021","study_completion_date":" 11/22/2021","last_update_posted":"2022-08-03"},{"id":"4ef48f61-5d9b-4748-ac8d-85d8505fc2d7","acronym":"","url":"https://clinicaltrials.gov/study/NCT04743388","created_at":"2021-02-08T13:52:22.089Z","updated_at":"2024-07-02T16:36:13.267Z","phase":"","brief_title":"Study of the Kinetics of Antibodies Against COVID-19 (SARS-CoV-2) and of Cellular Subpopulations of the Immune System","source_id_and_acronym":"NCT04743388","lead_sponsor":"National and Kapodistrian University of Athens","biomarkers":" IL6 • TNFA • CD14 • IL1B • CRP","pipe":"","alterations":" ","tags":["IL6 • TNFA • CD14 • IL1B • CRP"],"overall_status":"Recruiting","enrollment":" Enrollment 600","initiation":"Initiation: 01/04/2021","start_date":" 01/04/2021","primary_txt":" Primary completion: 08/01/2022","primary_completion_date":" 08/01/2022","study_txt":" Completion: 12/01/2022","study_completion_date":" 12/01/2022","last_update_posted":"2022-04-11"},{"id":"b2290004-6a3b-4c7e-a7e3-aba3da3fec16","acronym":"","url":"https://clinicaltrials.gov/study/NCT01423851","created_at":"2022-03-09T16:52:40.614Z","updated_at":"2024-07-02T16:36:15.706Z","phase":"Phase 1/2","brief_title":"Safety and Tolerability Study of Oral NS-018 in Patients With Primary Myelofibrosis (MF), Post-polycythemia Vera MF or Post-essential Thrombocythemia MF","source_id_and_acronym":"NCT01423851","lead_sponsor":"NS Pharma, Inc.","biomarkers":" JAK2 • CD8 • IL6 • STAT3 • CD14","pipe":" | ","alterations":" JAK2 V617F","tags":["JAK2 • CD8 • IL6 • STAT3 • CD14"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e JAK2 V617F"],"overall_status":"Completed","enrollment":" Enrollment 77","initiation":"Initiation: 06/01/2011","start_date":" 06/01/2011","primary_txt":" Primary completion: 04/22/2020","primary_completion_date":" 04/22/2020","study_txt":" Completion: 04/22/2020","study_completion_date":" 04/22/2020","last_update_posted":"2022-03-09"},{"id":"3f1dc61e-e2f1-443c-8183-3acd9f434fbc","acronym":"","url":"https://clinicaltrials.gov/study/NCT03369301","created_at":"2021-01-18T16:37:46.259Z","updated_at":"2024-07-02T16:36:16.277Z","phase":"","brief_title":"The Effect of Subcutaneous Immunoglobulin Gammanorm on the Distribution of IgG Subclasses and on Immunity of Patients With Secondary Immunodeficiency","source_id_and_acronym":"NCT03369301","lead_sponsor":"Octapharma","biomarkers":" CD8 • CD4 • NCAM1 • CD14 • CD27","pipe":"","alterations":" ","tags":["CD8 • CD4 • NCAM1 • CD14 • CD27"],"overall_status":"Completed","enrollment":" Enrollment 102","initiation":"Initiation: 09/25/2017","start_date":" 09/25/2017","primary_txt":" Primary completion: 11/22/2019","primary_completion_date":" 11/22/2019","study_txt":" Completion: 11/22/2019","study_completion_date":" 11/22/2019","last_update_posted":"2022-03-02"},{"id":"b1fc3749-e95d-4a68-ab16-6259c58fc366","acronym":"","url":"https://clinicaltrials.gov/study/NCT05011097","created_at":"2021-08-18T14:53:35.366Z","updated_at":"2024-07-02T16:36:26.202Z","phase":"Phase 1","brief_title":"A Phase I Clinical Trial of Y150 in the Treatment of Relapsed or Refractory Multiple Myeloma","source_id_and_acronym":"NCT05011097","lead_sponsor":"Wuhan YZY Biopharma Co., Ltd.","biomarkers":" IFNG • IL6 • TNFA • PTPRC • CD69 • IL2 • NCAM1 • IL10 • CD14 • IFNA1","pipe":"","alterations":" ","tags":["IFNG • IL6 • TNFA • PTPRC • CD69 • IL2 • NCAM1 • IL10 • CD14 • IFNA1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Y150"],"overall_status":"Recruiting","enrollment":" Enrollment 75","initiation":"Initiation: 07/08/2021","start_date":" 07/08/2021","primary_txt":" Primary completion: 07/30/2023","primary_completion_date":" 07/30/2023","study_txt":" Completion: 12/30/2024","study_completion_date":" 12/30/2024","last_update_posted":"2021-08-18"},{"id":"4e579bc4-0edb-4785-98c5-7919d0eac97b","acronym":"DOMEC","url":"https://clinicaltrials.gov/study/NCT03951415","created_at":"2021-04-01T23:53:05.952Z","updated_at":"2025-02-25T15:08:32.159Z","phase":"Phase 2","brief_title":"Durvalumab and Olaparib in Metastatic or Recurrent Endometrial Cancer","source_id_and_acronym":"NCT03951415 - DOMEC","lead_sponsor":"Leiden University Medical Center","biomarkers":" PD-1 • LAG3 • CTLA4 • CD163 • CD14 • CD68 • ITGAE • KLRB1 • KLRC1","pipe":"","alterations":" ","tags":["PD-1 • LAG3 • CTLA4 • CD163 • CD14 • CD68 • ITGAE • KLRB1 • KLRC1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Lynparza (olaparib) • Imfinzi (durvalumab)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 55","initiation":"Initiation: 07/08/2019","start_date":" 07/08/2019","primary_txt":" Primary completion: 08/01/2021","primary_completion_date":" 08/01/2021","study_txt":" Completion: 08/01/2021","study_completion_date":" 08/01/2021","last_update_posted":"2021-04-01"},{"id":"ae04c4b0-5e58-41e5-a5a2-7672c264f891","acronym":"","url":"https://clinicaltrials.gov/study/NCT01643850","created_at":"2021-01-18T07:04:45.792Z","updated_at":"2024-07-02T16:36:36.582Z","phase":"Phase 2","brief_title":"MCS110 in Patients With Pigmented Villonodular Synovitis (PVNS)","source_id_and_acronym":"NCT01643850","lead_sponsor":"Novartis Pharmaceuticals","biomarkers":" CSF1 • CD14","pipe":"","alterations":" ","tags":["CSF1 • CD14"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e lacnotuzumab (MCS110)"],"overall_status":"Completed","enrollment":" Enrollment 36","initiation":"Initiation: 04/23/2012","start_date":" 04/23/2012","primary_txt":" Primary completion: 12/07/2017","primary_completion_date":" 12/07/2017","study_txt":" Completion: 12/21/2018","study_completion_date":" 12/21/2018","last_update_posted":"2021-01-05"}]